-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Teams Up with Mount Sinai to Boost Cancer Immunotherapy Research

Benzinga·02/03/2025 12:12:13
Listen to the news

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today that it has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai ("Icahn School of Medicine") in New York, NY, to explore the immunoregulation of NK and T cells within the TME by Purple's CAPTN-3 multi-specific engagers with the purpose of enhancing tumor-specific immunity against various cancer types.